Talphera Inc.
Deschisă
0.88 -2.22
Rezumat
Modificarea prețului
24h
Minim
0.85
Maxim
0.92
Venit | 664K -3.8M |
|---|---|
Marjă de profit | -443,600 |
Angajați | 12 |
Recomandări | Puternic Cumpărare |
|---|---|
Prognoză pe 12 luni | +268.6% upside |
Capitalizare de piață | 5.7M 39M |
|---|---|
Deschiderea anterioară | 3.1 |
Închiderea anterioară | 0.88 |
Talphera Inc. Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Talphera Inc. Așteptări
Obiectiv de preț
By TipRanks
268.6% sus
Prognoză pe 12 luni
Medie 3.17 USD 268.6%
Maxim 3.5 USD
Minim 3 USD
În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTalphera Inc. - Dist în ultimele 3 luni.
Date financiare
Cheltuieli de vânzare și administrare
Profit pre-impozitare
Vânzări
Cheltuieli cu dobânzile pe datorie
Profit operațional
$
Despre Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
